PCOS: Periods, Skin and Hair, Fertility, and Metabolic Health

Polycystic ovary syndrome is among the most common endocrine conditions in women of reproductive age and among the most misunderstood, largely because of what it is called.

The name is wrong in two directions

The structures seen on ultrasound are not cysts in the ordinary sense — they are small follicles that have not matured and released an egg. Many women with the condition never show that appearance. Many women without the condition do. An ultrasound report describing polycystic-appearing ovaries is one piece of information, not a diagnosis.

The 2023 international guideline simplified this. Where irregular menstrual cycles and signs of excess androgen are both present, the diagnosis is made on those two features and ultrasound is not required. In adults, anti-Müllerian hormone (AMH) testing is now accepted as an alternative to ultrasound. In adolescents, both irregular cycles and excess androgen are required, and ultrasound and AMH are specifically not recommended because they are not specific enough at that age. Conditions that mimic the picture, including thyroid disease and elevated prolactin, still need excluding.

The guideline also created a category worth knowing: someone with only one of the two features is described as “at risk of PCOS” and warrants follow-up rather than dismissal. Being told you have it on the strength of a scan alone, or being told you do not because a scan looked normal, are both reasons to ask which criteria were applied.

The metabolic half

This is the part most often left out, and it is why the condition matters beyond fertility. The 2023 guideline strengthened recognition of the broader features: metabolic risk factors, diabetes, cardiovascular disease and sleep apnoea are all increased, and it recommends that individuals with PCOS be recognised as having increased cardiovascular disease risk factors and cardiovascular disease. It calls for a lifelong health plan rather than care that ends when childbearing does, with screening at diagnosis and repeat screening guided by clinical judgement, risk factors, comorbidities and life stage.

One point cuts against a common expectation. Insulin resistance is recognised as a key feature, but the guideline states that routinely available measures of it are inaccurate and that clinical measurement is not currently recommended. If you have been told your insulin test was normal and therefore you do not have the condition, that reasoning does not follow.

Two further items belong in a lifelong plan. Depression and anxiety are significantly increased, and the guideline recommends screening for them in everyone with the condition. And there is an increased premenopausal risk of endometrial cancer, though the absolute risk remains low — which is part of why persistently absent periods are worth addressing rather than ignoring.

Skin and hair are part of it

Acne that persists past the teenage years or sits along the jawline, hair growth in a male pattern, and scalp thinning are features of the condition rather than separate cosmetic problems. Treating them in isolation — a dermatology plan with no endocrine assessment, or the reverse — is why some women cycle between clinics for years. Coordinated care works better because the same underlying pattern drives all of it.

Fertility, and the misunderstanding that costs most

Irregular ovulation makes conception less predictable, and many women with the condition do need help conceiving. But irregular is not never. Ovulation can occur unpredictably, pregnancy can occur unexpectedly, and women who have been told they will struggle to conceive are sometimes given no contraception at all as a result. If pregnancy is not currently wanted, contraception is still required.

What actually helps

Treatment is directed by which features are troubling you and whether pregnancy is a current goal, and the same woman may need entirely different management at different stages of life. The categories worth being able to name are these.

• Lifestyle measures, which the guideline maintains as a foundation — and it makes the point explicitly that there are benefits to a healthy lifestyle even in the absence of weight loss, alongside awareness of weight stigma.
• Combined hormonal contraception, used to regulate cycles and to address androgen-driven skin and hair features.
• Metformin, which the guideline says could be used in preference to combined oral contraception where the indication is metabolic.
• Ovulation induction where fertility is the goal, with the guideline emphasising cheaper and safer fertility management.
• Psychological assessment and therapy where screening identifies depression or anxiety.

Which of these applies to you, in what form and at what dose, is a prescribing decision. The purpose of naming them is so you can ask which one a proposed treatment is, and why that one.

What to bring

• A cycle record over several months, however irregular
• Which feature bothers you most — periods, skin, hair, weight, or fertility
• Family history of diabetes, and of the same features in relatives
• Whether pregnancy is a current goal, a future one, or not wanted
• Any previous hormone results or scan reports, with the actual numbers

Main takeaway

A scan alone does not diagnose it and normal-looking ovaries do not exclude it. Take the metabolic side as seriously as the reproductive side, treat the skin and hair features as part of the same condition, and keep using contraception if you do not want to be pregnant.